Daily Stock Opinions and Ratings

Opinions

Andrew McCreath Neurochem NRM-T DON'T BUY Jul 08, 2004

Feels it's a little pricey at these levels given where they are in the development of their program. Have some interesting programs.

Andrew McCreath

Unlock Rating

$28.680

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY

Has a very strong range of products.

TOP PICK

Into phase 3 trial. All cashed up. Will start to be getting attention.

PAST TOP PICK

(A top pick Sept 9/03. Up 58%.) As a potential treatment for Alzheimer's. Good technology. Has some US financing which will get US investors interested.

PAST TOP PICK

(A top pick Sept 9/03. Up100 %.) Still likes. The market opportunity is so big, would still buy at this price.

BUY

Has been moving sideways which, for a biotech, is not too bad. The company has good backing. Should see considerable upside.

BUY

There has been a general selloff of biotech stocks. Still believe in this company.

DON'T BUY

Looking at his relative performer chart, it's been an underperformer. Has negative money flow. In a very clear downtrend.

SELL

He likes it, the only downside is that because the Japaneese market has risen 40% over the last year, it's a bit expensive right now. He suggests going to a different fund which is not so centered on the Japaneese market.

COMMENT

The name of the company was indistinct and this is the closest result in the data base. It is a biotech company focused on brain health. It acquired an AI company called Metro Mark. It is signing more and more deals with pharmaceutical companies for up-front and royalty payments.

Most Recent Experts

Michael Hakes - CFA, MBA

Murray Wealth Group

Daniel Straus

National Bank Financial

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Stan Wong

Private Wealth Management, ScotiaMcleod

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Andrew McCreath Neurochem NRM-T DON'T BUY Jul 08, 2004

You might be interested:

Neurochem(NRM-T)

Neurochem(NRM-T)

Neurochem(NRM-T)

Neurochem(NRM-T)

Neurochem(NRM-T)

Neurochem(NRM-T)

Neurochem(NRM-T)

Neurochem(NRM-T)

Neurochem(NRM-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Michael Hakes - CFA, MBA

Daniel Straus

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Stan Wong